52 Week Range
As of on the New York Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Boston Scientific Announces FDA Approval Of Imageready Mri For Vercise Gevia Deep Brain Stimulation System
Boston Scientific Says Submitted Borrowing Request For $2 Bln To Be Funded On Aug 19
Boston Scientific Closes Acquisition Of BTG Plc
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.
Medical Equipment & Supplies
300 BOSTON SCIENTIFIC WAY
Michael F. Mahoney
Chairman of the Board, President, Chief Executive Officer
Daniel J. Brennan
Chief Financial Officer, Executive Vice President
Kevin J. Ballinger
Executive Vice President and Global President - Interventional Cardiology
Joseph M. Fitzgerald
Executive Vice President and President - Rhythm Management
Edward F. Mackey
Executive Vice President - Operations
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A federal judge has sanctioned Boston Scientific Corp for "deliberately" failing to disclose the identity of a potential "central witness" to lawyers representing a whistleblower who had accused the company of selling defective cardiac defibrillators.
Boston Scientific is fighting a bid by the law firm Susman Godfrey and its co-counsel to force the medical device manufacturer to pay an "exorbitant" $7.62 million award to cover their fees and expenses for a whistleblower lawsuit that settled for $2.5 million.
Boston Scientific Corp <BSX.N> narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions.
U.S. medical device maker Boston Scientific Corp reported a 72.3% drop in second-quarter profit on Wednesday, hit by charges related to its acquisition of Britain's BTG Plc.
Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.
Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in a joint statement on Tuesday.
A federal jury in Delaware has ordered medical device maker Edwards Lifesciences Corp to pay $35 million after finding a heart valve replacement system it makes infringes a patent held by rival Boston Scientific Corp.
US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn (US$4.22bn)bridge loan from Barclays Bank.
US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn bridge loan from Barclays Bank.
U.S. medical device maker Boston Scientific Corp <BSX.N> has agreed to buy Britain's BTG Plc <BTG.L> for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio.
U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash.
Medical device company Boston Scientific Corp <BSX.N> posted a slightly better-than-expected quarterly profit on Wednesday, helped by higher sales in its MedSurg business, which makes surgical products for various urological and pelvic disorders.
Medical device maker Boston Scientific Corp posted a 52.7 percent jump in quarterly profit on Wednesday, helped by higher sales in its cardiovascular business, which makes stents and heart valves.
Medical device maker Stryker Corp <SYK.N> is not in talks to buy rival Boston Scientific Corp <BSX.N>, the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced.
Medical device maker Stryker Corp was not in discussions to buy rival Boston Scientific Corp, Stryker said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday.
Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.
Device maker Stryker Corp has made a takeover approach to Boston Scientific Corp, the Wall Street Journal reported https://www.wsj.com/articles/stryker-has-made-a-takeover-approach-to-boston-scientific-1528727749?mod=searchresults&page=1&pos=1, citing sources.
* JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN ALLERGAN PLC OF 12,000 SHARES - SEC FILING
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.